Have a Claim?

Click here for a confidential contact or call:

1-212-350-2774

July 31, 2020

Posted  July 31, 2020

Canadian company Bausch Health, formerly known as Valeant Pharmaceuticals, will pay a $45 million penalty to resolve charges that its executives engaged in improper revenue recognition and misleading disclosures in SEC filings and earnings presentations between 2014 and 2015.  The company was alleged to have recorded false sales of products to specialty pharmacy Philidor Rx Services and its affiliates, which were controlled by Valeant.  In addition, Valeant allegedly misrepresented the source and materiality of revenue it received following a 500% increase in the price of its diabetes drug Glumetza.  Former CEO J. Michael Pearson will pay a civil penalty of $250,000; former CFO Howard B. Schiller will pay a civil penalty of $100,000; former controller Tanya Carro will pay a civil penalty of $75,000.  The individuals also agreed to return specified portions of their incentive compensation to the company.  SEC

Tagged in: Accounting Fraud, Drug and DME Pricing, Financial and Investment Fraud, Misrepresentations, Pharma Fraud, Securities Fraud,

Newsletter

Subscribe to receive email updates from the Constantine Cannon blogs

Sign up for: